Roth Capital analyst Suji Desilva raised the firm’s price target on MaxLinear (MXL) to $18 from $11 and keeps a Neutral rating on the shares. MaxLinear reported and guided revenue ahead of consensus, reflecting recovery and growth driver benefits in core segments., the analyst tells investors in a research note. The company remains on track for strong optical growth this year with continued program ramp into CY26, Roth says.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MXL:
- Positive Outlook for Maxlinear: Buy Rating Supported by Strong Recovery and Growth Prospects
- MaxLinear price target raised to $18 from $13 at Wells Fargo
- MaxLinear Reports Strong Q2 2025 Financial Results
- MaxLinear price target raised to $18 from $11 at Roth Capital
- MaxLinear reports Q2 EPS 2c, consensus 2c